Hyperkalemia in the Hypertensive Patient

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Hyperkalemia is a common complication in patients with systemic arterial hypertension (HTN), particularly those with chronic kidney disease (CKD), diabetes mellitus (DM), or heart failure (HF).
• Pharmacological therapies, especially renin-angiotensin-aldosterone inhibitors (RAASi), can interfere with potassium homeostasis, increasing hyperkalemia risk.
• Hyperkalemia significantly contributes to morbidity, including emergency department visits and hospitalizations, and is associated with increased mortality risk.

Purpose of the Study:

• Identify risk factors for hyperkalemia in patients with HTN.
• Evaluate the risk-benefit profile of RAASi in specific patient populations.
• Outline preventive and therapeutic strategies for managing hyperkalemia.

Main Methods:

• Review of current literature on hyperkalemia risk factors and management.
• Analysis of evidence supporting the use of novel cation-exchange resins.
• Assessment of safety and efficacy data for patiromer and sodium zirconium cyclosilicate.

Main Results:

• Novel cation-exchange polymers (patiromer, sodium zirconium cyclosilicate) demonstrate safety and efficacy.
• These agents enable continued RAASi therapy in patients who develop hyperkalemia.
• This allows patients to maintain beneficial RAASi treatment without necessitating drug withdrawal.

Conclusions:

• Cation-exchange polymers offer a new, safe strategy for managing hyperkalemia in patients requiring RAASi.
• These therapies facilitate the continuation of RAASi, optimizing treatment for conditions like HTN, CKD, DM, and HF.
• Effective hyperkalemia management with novel agents improves patient outcomes and adherence to guideline-directed medical therapy.